The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 01, 2015
Filed:
Mar. 18, 2011
Young Woo Park, Daejeon, KR;
Ki Won JO, Gyeonggi-do, KR;
Srok Ho Yoo, Daejeon, KR;
Jung Yu, Daejeon, KR;
Sun-ha Yoon, Daejeon, KR;
Ji Hyun Park, Daejeon, KR;
Eun Jung Song, Daejeon, KR;
Jong-ho Lee, Gyeonggi-do, KR;
Min Ji Seo, Seoul, KR;
Sun Jung Cho, Gyeonggi-do, KR;
MI LA Cho, Seoul, KR;
Ho Youn Kim, Seoul, KR;
MI Kyung Park, Gyeonggi-do, KR;
Hye Jwa OH, Seoul, KR;
Jin Sil Park, Seoul, KR;
Yun Ju Woo, Seoul, KR;
Jae Kyeong Byun, Chungcheongbuk-do, KR;
Jun Geol Ryu, Gangwon-do, KR;
Young Woo Park, Daejeon, KR;
Ki Won Jo, Gyeonggi-do, KR;
Srok Ho Yoo, Daejeon, KR;
Jung Yu, Daejeon, KR;
Sun-Ha Yoon, Daejeon, KR;
Ji Hyun Park, Daejeon, KR;
Eun Jung Song, Daejeon, KR;
Jong-Ho Lee, Gyeonggi-do, KR;
Min Ji Seo, Seoul, KR;
Sun Jung Cho, Gyeonggi-do, KR;
Mi La Cho, Seoul, KR;
Ho Youn Kim, Seoul, KR;
Mi Kyung Park, Gyeonggi-do, KR;
Hye Jwa Oh, Seoul, KR;
Jin Sil Park, Seoul, KR;
Yun Ju Woo, Seoul, KR;
Jae Kyeong Byun, Chungcheongbuk-do, KR;
Jun Geol Ryu, Gangwon-do, KR;
Abstract
The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.